about
THERAPY OF ENDOCRINE DISEASE: Endocrine dilemma: management of Graves' orbitopathyMANAGEMENT OF ENDOCRINE DISEASE: Rituximab therapy for Graves' orbitopathy - lessons from randomized control trialsDesign, validation and efficacy of bisubstrate inhibitors specifically affecting ecto-CK2 kinase activity.Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO.Teprotumumab for Thyroid-Associated Ophthalmopathy.Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves' orbitopathy: a randomized controlled study.Echographic diagnosis of pretibial myxedema in patients with autoimmune thyroid disease.Nature of 64 kDa eye muscle and thyroid membrane proteins and their significance in thyroid-associated ophthalmopathy--an hypothesis.The 2016 European Thyroid Association/European Group on Graves' Orbitopathy Guidelines for the Management of Graves' OrbitopathyThyroid-associated ophthalmopathy--a model for the association of organ-specific autoimmune disorders.Immunotherapy for Graves' ophthalmopathy.A Comparative Analysis and Review of lysyl Residues Affected by Posttranslational ModificationsTolterodine in the Treatment of Male LUTS.Medical Treatment of Graves' Orbitopathy.Graves' orbitopathy as a rare disease in Europe: a European Group on Graves' Orbitopathy (EUGOGO) position statement.Dissecting the Role of K61/K59 Residue in VPS4 Functions.B Cell Activating Factor (BAFF) and BAFF Receptor Expression in Autoimmune and Nonautoimmune Thyroid Diseases.The Impact of Central Obesity on Storage Luts and Urinary Incontinence After Prostatic Surgery.Does early response to intravenous glucocorticoids predict the final outcome in patients with moderate-to-severe and active Graves' orbitopathy?Structural and Dynamic Characterization of the Molecular Hub Early Region 1A (E1A) from Human Adenovirus.Cytokines (interferon-γ and tumor necrosis factor-α)-induced nuclear factor-κB activation and chemokine (C-X-C motif) ligand 10 release in Graves disease and ophthalmopathy are modulated by pioglitazone.PREGO (presentation of Graves' orbitopathy) study: changes in referral patterns to European Group On Graves' Orbitopathy (EUGOGO) centres over the period from 2000 to 2012.Patients with endocrine ophthalmopathy not associated with overt thyroid disease have multiple thyroid immunological abnormalities.CK2 is a key regulator of SLC4A2-mediated Cl-/HCO3- exchange in human airway epithelia.Beliefs, Knowledge, Implementation, and Integration of Evidence-Based Practice Among Primary Health Care Providers: Protocol for a Scoping Review.Statins may increase the risk of liver dysfunction in patients treated with steroids for active graves' orbitopathy.Serum BAFF concentrations in patients with Graves' disease and orbitopathy before and after immunosuppressive therapy.Rituximab treatment in patients with active Graves' orbitopathy: effects on proinflammatory and humoral immune reactions.Future Research in Graves' Orbitopathy: From Priority Setting to Trial Design Through Patient and Public Involvement.A quantitative method for assessing the degree of axial proptosis in relation to orbital tissue involvement in Graves' orbitopathy.Isotype and immunoglobulin subclass distribution of eye muscle membrane reactive antibodies in the serum of patients with thyroid-associated ophthalmopathy as detected in Western blotting.A new role for sphingosine: Up-regulation of Fam20C, the genuine casein kinase that phosphorylates secreted proteins.The acidophilic kinases PLK2 and PLK3: structure, substrate targeting and inhibition.Role of the eye muscles in thyroid eye disease: identification of the principal autoantigens.Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves' orbitopathy (MINGO): a randomised, observer-masked, multicentre trial.Fully Automated Muscle Ultrasound Analysis (MUSA): Robust and Accurate Muscle Thickness Measurement.Classification and prediction of the progression of thyroid-associated ophthalmopathy by an artificial neural network.Proteomics perturbations promoted by the protein kinase CK2 inhibitor quinalizarin.The therapeutic outcome to intravenous steroid therapy for active Graves' orbitopathy is influenced by the time of response but not polymorphisms of the glucocorticoid receptor.Combining micro-RNA and protein sequencing to detect robust biomarkers for Graves' disease and orbitopathy.
P50
Q26749195-9BBF7FF3-5FE9-42BF-B5BB-DBA726E6941CQ28077018-877616EC-84D6-4C4D-8EFE-363E6FEC2C78Q30992224-27F8D0E8-A189-4DE0-92CE-7D228204B11EQ34010116-83807643-37A2-479B-B387-F86164496670Q34556184-1477F348-01C8-4F00-B6E4-65E8B6728563Q35055076-0F4A5EF9-7079-44C5-B7BC-10E825762CABQ36738946-E0B36E04-974B-4007-8EE3-4EF3E60F5203Q36749737-BC3815A3-AA87-4CC3-8DF2-58EBA97E5326Q36811289-1FDA3225-9CA1-4750-91EB-678818393D85Q37264285-8DBE6053-AC6B-45F3-AC2A-664A08A56F58Q38238204-3E21DA45-6648-4A66-827F-9E4C2B6CBD31Q38530761-DF7CD95A-3FD6-4C37-96E1-DD96D4700AF4Q38543432-BE9C8F5E-380D-4B3E-B52A-E6F759C509E7Q38585021-C19D216C-9CAA-47C0-B289-DC969F0D8C6CQ38692635-6A03BA02-902A-4589-9207-3F7B271802B7Q38782262-3A88F426-2885-41C1-B122-7A0D5F397B19Q38848883-A8624659-1728-4CC1-8669-32B837C6CD6AQ38901781-619C9ED7-A5AB-41C2-B071-D861CECE2A5BQ38972962-B0004A94-2A69-401A-AA3E-8BDE95D419E7Q39524967-62C90373-BA89-4EBB-A192-3291CFC44502Q39894512-9F9BA286-6144-49F5-80F9-81B9959A4B3DQ40962257-908B554F-F54D-4A34-86D1-8B9CFBABA0FAQ41222380-FBD82CEB-AAF8-49D4-87EF-D29F54CADA1BQ41368424-8E15292B-2F1C-4075-AF2A-ADC1A4CE295EQ41424773-717F4A56-19C0-4652-8073-3748D5830F9CQ42156382-F6177DDB-706C-4DF8-A059-6EA2F8B8AC43Q42503142-80F15128-54AC-4F02-A3D8-46E79F5224B8Q43042591-238E1E48-929B-4B0C-A660-189D1055CCCAQ43165236-2BBF88FE-E2DB-4C8D-8460-F15D3CA9C2C7Q44463190-808FFA8F-EE1B-44A7-8B82-5DCCD8F5863CQ44582264-AA11178C-C430-415B-AFC8-F7CC47FA1C54Q46904545-59F77597-695F-44F1-A7C1-E78FB928326BQ47714271-FF8CF2AF-B6FB-4150-8DF5-BD3BB1011FC7Q47822465-ADAF7A3A-EBB7-4D35-A4E9-777E294B58D7Q49360067-D1BD15C8-317D-4133-A14B-E5569F187A22Q50574827-020797EF-B954-4413-B0C5-A7D99CCEF188Q52033511-BE0AB557-AEC1-4C90-A307-6DCA90E7F653Q54277503-2A38542A-C05C-4674-B2F0-55374B741CD5Q54756129-603752BF-2609-477A-9A93-76FB71983CB0Q54962508-337EC7EE-A6C4-450A-B36A-61FB708E754F
P50
description
researcher ORCID ID = 0000-0002-0276-0367
@en
wetenschapper
@nl
name
Mario Salvi
@ast
Mario Salvi
@en
Mario Salvi
@es
Mario Salvi
@nl
type
label
Mario Salvi
@ast
Mario Salvi
@en
Mario Salvi
@es
Mario Salvi
@nl
prefLabel
Mario Salvi
@ast
Mario Salvi
@en
Mario Salvi
@es
Mario Salvi
@nl
P106
P21
P31
P496
0000-0002-0276-0367